跳至主要内容
临床试验/NCT00002090
NCT00002090已完成不适用

An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

Pfizer6 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
试验地点
6

研究概览

简要总结

To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Concurrent Medication:
  • •Medications allowed under a Treatment IND program.
  • •Patients must have:
  • •HIV infection.
  • •Disseminated Mycobacterium avium Complex.
  • •Fever (> 100 degrees F) that cannot be attributed to another active infection, and at least one other constitutional symptom (such as fatigue, malaise, anorexia).
  • •Life expectancy of at least the duration of the study.
  • •Consent of parent or guardian if below the legal age of consent.

排除标准

  • •Co-existing Condition:
  • •Patients with the following symptoms and conditions are excluded:
  • •Known hypersensitivity or significant intolerance to macrolide antibiotics.
  • •Inability to take oral medications or a current condition likely to interfere with drug absorption (e.g., gastrectomy).
  • •Prior Medication:
  • •Treatment with an immunostimulant or immunomodulator compound such as alpha-interferon, gamma-interferon, or any interleukin within 7 days prior to study entry.
  • •Any other antibiotic with known activity against M. avium within 7 days prior to study entry.
  • •Not expected to comply with the requirements of the protocol, in the opinion of the investigator.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (6)

Loading locations...

相似试验